Drug intelligence / Profile preview

Inactivated COVID-19 vaccine (Kocak Farma)

Development stage: Phase 1
Lead developer: Kocak Farma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

An inactivated SARS-CoV-2 vaccine developed by Kocak Farma for the prevention of COVID‑2019 infections. The vaccine uses an inactivated form of the coronavirus and includes an adjuvant, likely aluminum salts, to enhance immune response. Its mechanism involves presenting SARS-CoV‑2 antigen to the immune system, stimulating both humoral and cellular immunity and inducing neutralizing antibodies against the virus. The primary indication is prophylaxis against COVID‑19. As of early 2025, it has been evaluated in phase 1 clinical trials but is not yet approved for use[1][2][3][4][8].

Other names: inactivated COVID-19 vaccine (Kocak Farma)Koçak Farma: Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine

Beyond the preview

Go deeper on Inactivated COVID-19 vaccine (Kocak Farma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inactivated COVID-19 vaccine (Kocak Farma).

Explore the full profile